New version of Quimio-Vio vaccine for adult population in clinical trial
- Written by Redacción ¡ahora!
- Category: Health
- Hits: 942
After receiving the authorization of the Center for State Control of Medicines, Equipment and Medical Devices (Cecmed) and the approval of the Ministry of Public Health, a phase II-III clinical trial began at the Institute of Hematology and Immunology, aimed at evaluating the safety, immunogenicity and efficacy of a new version of the Cuban anti-pneumococcal vaccine Quimio-Vio, in adults from 50 to 74 years of age.